Management of Medullary Thyroid Carcinoma

Publication Date: June 3, 2015
Last Updated: October 9, 2023

Diagnosis

The current ATA risk categories for hereditary MTC should be changed. ( C )
  • The current level D category should be changed to a new category, “highest risk” (HST), that includes patients with MEN2B and the RETcodon M918T mutation.
  • The current level C category should be changed to a new category, “high risk” (H), that includes patients with MEN 2A and RETcodon C634 mutations.
  • The current level A and B categories should be combined into a new category “moderate risk” (MOD) that includes patients with hereditary MTC and RETcodon mutations other than M918T and C634.
625

Treatment

Patients with MTC and no evidence of neck lymph node metastases by US examination and no evidence of distant metastases should have a total thyroidectomy and dissection of the lymph nodes in the central compartment (level VI). ( B )
625

Overview

Title

Management of Medullary Thyroid Carcinoma

Authoring Organization

American Thyroid Association